002022 Shanghai Kehua Bio-engineering
WatchlistShanghai Kehua Bio-engineering News
[BT Financial Report Instantaneous Analysis] Kehua Biotech's 2023 Quarterly Report: Balance Ratio Declines, Operating Income and Net Profit Are Under Pressure
This financial report was announced on 2023-10-27 19:37:28 Kehua Biotech (stock code: 002022) is a medical device company focusing on the manufacture of in vitro diagnostic products, mainly engaged in R&D, production and sales of in vitro diagnostic reagents and medical testing instruments. In vitro diagnosis plays an important role in clinical diagnosis. It can provide important reference indicators for doctors' treatment plans and medication, and at the same time save medical expenses. Judging from Kehua Biotech's 2023 three-quarter report, the company's total assets fell from 8.813 billion yuan at the end of the previous year to 7.038 billion yuan and liabilities at the end of the reporting period
Kehua Biotech (002022.SZ): No share repurchase has been implemented
Gelonghui November 2 | Kehua Biotech (002022.SZ) announced that as of October 31, 2023, the company has not implemented a share repurchase.
Kehua Biotech (002022.SZ): Plans to repurchase 100 million yuan to 200 million yuan of company shares
On October 30, Gelonghui Biotech (002022.SZ) announced that the company plans to use its own capital to repurchase the company's shares through centralized bidding transactions for equity incentives or employee stock ownership plans. The total capital of this repurchase is not less than RMB 10,000 million (inclusive) and no more than RMB 20 million (inclusive); the price of the repurchased shares is no more than RMB 11 per share (inclusive). The specific number of shares to be repurchased is based on the actual number of shares repurchased at the end of the repurchase period or when the repurchase of shares is completed. The share repurchase period starts from the date the board of directors deliberates and approves the share repurchase plan1
Kehua Biotech (002022.SZ): Achieved revenue of 508 million yuan in the third quarter, a year-on-year decrease of 65.44%
On October 27, Gelonghui Biotech (002022.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 508 million yuan, a year-on-year decrease of 65.44%; net profit attributable to shareholders of listed companies was -41.082 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -44,7292 million yuan; basic earnings per share was -0.0799 yuan.
KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit
SHANGHAI, Oct. 11, 2023 /PRNewswire/ -- Shanghai Kehua Bio-engineering Co., Ltd ("KHB" or "the Company", Stock code: 002022.SZ), China's leading In Vitro Diagnostic (IVD) company has achieved a signif
Kehua Biotech (002022.SZ): The subsidiary has products related to the detection of dengue virus nucleic acid based on fluorescence PCR technology
Glonghui, September 27丨Kehua Biology (002022.SZ) said on the investor interactive platform that the company currently has no NSI antigen reagent products for the dengue virus, and Tianlong, a holding subsidiary of the company, has products related to the detection of dengue virus nucleic acid based on fluorescence PCR technology.
Kehua Biotech (002022.SZ): There are currently no Nipah virus testing products
Glonghui September 22丨Kehua Biotech (002022.SZ) said on the investor interactive platform that the company currently has no Nipah virus testing products. The fluorescence PCR method is currently the main technology for detecting Hennipa virus. The company and its holding subsidiary Tianlong Company have accumulated technology in the field of fluorescence PCR technology.
Interpretation of Kehua Biotech's 2023 Interim Report: Revenue increased significantly, net profit was under pressure, and net cash flow declined sharply
According to Kehua Biotech's 2023 interim report, revenue for the reporting period was 1,396,475,774.51 yuan, up 54.66% from 902,928,251.87 yuan in the same period last year. This shows that the company has achieved significant growth in terms of business. However, net profit attributable to shareholders of listed companies for the reporting period was 21,128,073.92 yuan, down 54.50% from 46,430,948.61 yuan in the same period last year. Meanwhile, net profit attributable to shareholders of listed companies for the reporting period after deducting non-recurring profit and loss was 6,885,10
Kehua Biotech (002022.SZ) released its results for the first half of the year, with net profit of RMB 21.1881 million, a decrease of 54.50%
Kehua Biotech (002022.SZ) released its 2023 semi-annual report. During the reporting period, the company achieved operating income...
Shanghai Kehua Bio-Engineering Registers Hepatitis Detection Kit
Shanghai Kehua Bio-Engineering (SHE:002022) has obtained a medical device registration certificate for its new hepatitis B detection kit, according to a filing on Monday. The Chinese medical device ma
Kehua Biotech (002022.SZ): “Hepatitis B virus nucleic acid test kit (PCR-fluorescence probe method)” obtained medical device registration certificate
According to the Zhitong Finance App, Kehua Biology (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the State Drug Administration, involving the product “Hepatitis B virus nucleic acid test kit (PCR-fluorescence probe method)”, which is used to quantitatively detect hepatitis B virus nucleic acid (HBVDNA) in human serum or plasma samples.
Kehua Biotech (002022.SZ): Net profit expected to drop 44.00%-59.08% in the first half of the year
On July 12丨Kehua Biotech (002022.SZ) announced its 2023 semi-annual results forecast. Net profit attributable to shareholders of listed companies for the reporting period was 19 million yuan to 26 million yuan, down 44.00%-59.08% from the same period last year; net profit profit after deducting non-recurring profit and loss was RMB 0 million to 7 million yuan, down 84.37%-100.00% from the same period last year; basic earnings per share was 0.0369 yuan/share — 0.0506 yuan/share. During the reporting period, the company's continuous increase in R&D investment led to an increase in R&D expenses; at the same time, the company may be able to save
Kehua Biotech (002022.SZ): Calcitonin determination kit (chemiluminescence method) obtained medical device registration certificate
According to the Zhitong Finance App, Kehua Biotech (002022.SZ) announced that the company has received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the Shanghai Drug Administration. The product name is calcitonin determination kit (chemiluminescence) for medical institutions to quantitatively measure calcitonin (CT) concentration in human serum or plasma samples in vitro for auxiliary diagnosis.
Kehua Biotech (002022.SZ): Since 2014, there has been no actual controller, and the company's main business has developed steadily
Gelonhui June 7 丨 Kehua Biotech (002022.SZ) was surveyed by the agency and said, “Does the company have no actual controller influence on the company? After Zhuhai Insurance Union, a wholly-owned subsidiary of Gree Real Estate, became the company's largest shareholder, its position on the company?” The company replied that the company has not had an actual controller since 2014, and the company's main business has developed steadily. Gree Real Estate's investment in Kehua Biotech through its wholly-owned subsidiary is an important step forward in its biomedical and healthcare sector layout and improving and expanding its industrial layout in the big health sector. As Gree Real Estate, which has a background in state-owned assets, focuses on long-term development
Kehua Biotech (002022.SZ): Achieving zero breakthrough in the pet market is one of the company's 2023 business plans
Gelonghui, June 7 丨 Kehua Biotech (002022.SZ) was surveyed by the agency. During the Q&A session, “Does the company have a layout for the pet market?” The company replied that the rapid development of the Chinese pet market has led to a rise in demand for pet diagnosis and treatment. The company is developing biochemicals, coagulation, luminescent POCT and other products, and achieving a zero breakthrough in the pet market is one of the company's 2023 business plans.
Kehua Biology (002022.SZ): Currently, the company does not have Plasmodium falciparum antigen test kit products
Gelonghui, May 17 丨 An investor asked Kehua Biotech (002022.SZ) on the investor interactive platform, “Does your company have a Plasmodium falciparum antigen test kit?” Kehua Biotech replied that currently the company does not have Plasmodium falciparum antigen test kit products.
Kehua Biotech (002022.SZ): “Lipoprotein (a) Determination Kit (Latex Immune Turbidimetry)” obtained a medical device registration certificate
Gelonhui May 9 丨 Kehua Biology (002022.SZ) announced that recently, Shanghai Kehua Biotechnology Co., Ltd. received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the Shanghai Drug Administration as a lipoprotein (a) determination kit (latex immunoturbidimetry).
Kehua Biotech (002022.SZ) 2022 equity distribution: 6 yuan for every 10 shares, equity registration on May 9
According to the Zhitong Finance App, Kehua Biotech (002022.SZ) announced that the company's 2022 equity distribution plan is to distribute 6 yuan in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital after excluding repurchased shares. The equity distribution registration date for this equity distribution is: May 9, 2023, and the deduction date is: May 10, 2023.
Kehua Biotech (002022.SZ) released first-quarter results, with net profit of 54.7619 million yuan, an increase of 145.75% over the previous year
According to the Zhitong Finance App, Kehua Biotech (002022.SZ) released a report for the first quarter of 2023. The company's operating income during the reporting period was 833 million yuan, an increase of 98.13% over the previous year; net profit attributable to shareholders of listed companies was 54.7619 million yuan, an increase of 145.75% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 48.1412 million yuan, an increase of 130.37% over the previous year; basic earnings per share were 0.1065 yuan.
Kehua Bio-Engineering Registers Tumor Necrosis Testing Kit
01:50 AM EDT, 04/06/2023 (MT Newswires) -- Shanghai Kehua Bio-Engineering (SHE:002022) has obtained a drug registration certificate in China for its tumor necrosis testing kit, according to a filing o